Henglei Lu

572 total citations
20 papers, 429 citations indexed

About

Henglei Lu is a scholar working on Molecular Biology, Epidemiology and Cancer Research. According to data from OpenAlex, Henglei Lu has authored 20 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Epidemiology and 6 papers in Cancer Research. Recurrent topics in Henglei Lu's work include MicroRNA in disease regulation (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Nephrotoxicity and Medicinal Plants (3 papers). Henglei Lu is often cited by papers focused on MicroRNA in disease regulation (5 papers), Liver Disease Diagnosis and Treatment (4 papers) and Nephrotoxicity and Medicinal Plants (3 papers). Henglei Lu collaborates with scholars based in China. Henglei Lu's co-authors include Jin Ren, Likun Gong, Shouyan Wu, Xinming Qi, Zhouteng Tao, Yiting Zhang, Xiaoxia Yan, Yunxia Dong, Lei Fan and Shichao Cui and has published in prestigious journals such as Oncogene, International Journal of Molecular Sciences and Journal of Hepatology.

In The Last Decade

Henglei Lu

20 papers receiving 427 citations

Peers

Henglei Lu

EPIDE

PHARM

ONCOL

Zhifeng Zhao China

Kan Toriguchi Japan

Hong Luo China

Laura Ruíz-Cañas Spain

Xiaobin Mei China

Lizhi Lv China

Shiqiang Shen China

Juan Zou China

Yeon A. Choi South Korea

Mingming Meng China

Zhifeng Zhao China

Henglei Lu

141 ×0.7

66 ×0.6

EPIDE

83 ×0.8

40 ×0.5

PHARM

69 ×1.0

ONCOL

Citations per year, relative to Henglei Lu Henglei Lu (= 1×) peers Zhifeng Zhao

Countries citing papers authored by Henglei Lu

Since Specialization

Citations

This map shows the geographic impact of Henglei Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henglei Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henglei Lu more than expected).

Fields of papers citing papers by Henglei Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henglei Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henglei Lu. The network helps show where Henglei Lu may publish in the future.

Co-authorship network of co-authors of Henglei Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Henglei Lu. A scholar is included among the top collaborators of Henglei Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henglei Lu. Henglei Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

He, X., Wenfeng Liao, Xing Zhang, et al.. (2024). GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation. Acta Pharmacologica Sinica. 45(11). 2394–2404. 8 indexed citations

Lu, Henglei, et al.. (2022). HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis. Molecular Cancer Research. 20(12). 1724–1738. 4 indexed citations

Wu, Shouyan, et al.. (2022). Aberrant peribiliary gland niche exacerbates fibrosis in primary sclerosing cholangitis and a potential therapeutic strategy. Biomedicine & Pharmacotherapy. 153. 113512–113512. 1 indexed citations

Dong, Yunxia, Xiaoding Xu, Qian Wu, et al.. (2022). MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis. Molecular Biomedicine. 3(1). 25–25. 11 indexed citations

Shi, Jingying, Luyao Song, Henglei Lu, et al.. (2022). Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie–Baizhu Decoction. Frontiers in Pharmacology. 13. 858795–858795. 21 indexed citations

Tan, Rongrong, Jiayang Li, Lu Liu, et al.. (2022). CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice. International Journal of Molecular Sciences. 23(24). 15931–15931. 10 indexed citations

Yu, Xiaolu, Meng Liu, Ji Zhou, et al.. (2022). PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. Journal for ImmunoTherapy of Cancer. 10(10). e004590–e004590. 35 indexed citations

Wu, Shouyan, et al.. (2021). Prevention of D-GalN/LPS-induced ALI by 18β-glycyrrhetinic acid through PXR-mediated inhibition of autophagy degradation. Cell Death and Disease. 12(5). 480–480. 30 indexed citations

Liu, Yongzhen, Henglei Lu, Xinming Qi, et al.. (2021). Aristolochic acid I promoted clonal expansion but did not induce hepatocellular carcinoma in adult rats. Acta Pharmacologica Sinica. 42(12). 2094–2105. 8 indexed citations

10.

Guo, Huijie, Henglei Lu, Guanghui Wang, et al.. (2021). miR-34a-5p regulates PINK1-mediated mitophagy via multiple modes. Life Sciences. 276. 119415–119415. 19 indexed citations

11.

Liu, Yongzhen, Xianghuo He, Yuli Wang, et al.. (2021). Aristolochic acid I induces impairment in spermatogonial stem cell in rodents. Toxicology Research. 10(3). 436–445. 3 indexed citations

12.

Guo, Huijie, Henglei Lu, Guanghui Wang, et al.. (2020). Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy. Cell Death and Differentiation. 28(1). 320–336. 44 indexed citations

13.

Li, Yu, Huibiao Zhang, Lei Fan, et al.. (2020). MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell permeability. Oncogene. 39(17). 3473–3488. 35 indexed citations

14.

Fan, Lei, Rongtao Lai, Ningning Ma, et al.. (2020). miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder. Journal of Hepatology. 74(1). 8–19. 58 indexed citations

15.

Yan, Xiaoxia, Hailong Li, Yiting Zhang, et al.. (2019). A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice. Acta Pharmacologica Sinica. 41(3). 348–357. 30 indexed citations

16.

Dong, Yunxia, Henglei Lu, Qiang Li, et al.. (2019). (5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. Life Sciences. 232. 116644–116644. 17 indexed citations

17.

Zhang, Yiting, Minjia Tan, Yongzhen Liu, et al.. (2018). Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys. Molecular Therapy. 26(6). 1457–1470. 5 indexed citations

18.

Wu, Shouyan, Shichao Cui, Le Wang, et al.. (2018). 18β-Glycyrrhetinic acid protects against alpha-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway. Acta Pharmacologica Sinica. 39(12). 1865–1873. 61 indexed citations

19.

Liu, Yongzhen, Hao Wang, Jingjun Sun, et al.. (2013). A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats. Drug and Chemical Toxicology. 36(4). 443–450. 6 indexed citations

20.

Xue, Xiang, Ying Xiao, Likun Gong, et al.. (2008). Comparative 28-day repeated oral toxicity of Longdan Xieganwan, Akebia trifoliate (Thunb.) koidz., Akebia quinata (Thunb.) Decne. and Caulis aristolochiae manshuriensis in mice. Journal of Ethnopharmacology. 119(1). 87–93. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact